213 related articles for article (PubMed ID: 27146834)
21. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
22. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
24. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Duarte G; Tanus-Santos JE
Exp Mol Pathol; 2012 Apr; 92(2):217-21. PubMed ID: 22327101
[TBL] [Abstract][Full Text] [Related]
25. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease.
Morgan AR; Zhang B; Tapper W; Collins A; Ye S
J Mol Med (Berl); 2003 May; 81(5):321-6. PubMed ID: 12728308
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients.
Lacchini R; Jacob-Ferreira AL; Luizon MR; Coeli FB; Izidoro-Toledo TC; Gasparini S; Ferreira-Sae MC; Schreiber R; Nadruz W; Tanus-Santos JE
Clin Chim Acta; 2010 Dec; 411(23-24):1940-4. PubMed ID: 20707992
[TBL] [Abstract][Full Text] [Related]
27. MMP-9 Levels and IMT of Carotid Arteries are Elevated in Obese Children and Adolescents Compared to Non-Obese.
Andrade C; Bosco A; Sandrim V; Silva F
Arq Bras Cardiol; 2017 Mar; 108(3):198-203. PubMed ID: 28443954
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension.
Ritter AM; de Faria AP; Barbaro N; Sabbatini AR; Corrêa NB; Brunelli V; Amorim R; Modolo R; Moreno H
Blood Press; 2017 Apr; 26(2):122-129. PubMed ID: 27825280
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
[TBL] [Abstract][Full Text] [Related]
30. Role of extracellular matrix remodelling gene SNPs in keratoconus.
Abdullah OA; El Gazzar WB; Salem TI; Al-Kamil EA
Br J Biomed Sci; 2020 Jan; 77(1):13-18. PubMed ID: 31397194
[No Abstract] [Full Text] [Related]
31. Association study between matrix metalloproteinase-9 gene (MMP9) polymorphisms and the risk of Henoch-Schönlein purpura in children.
Xu ED; Xiao YF; Wang JJ; Dong L
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323137
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase-9 gene polymorphisms and their interaction with environment on subarachnoid hemorrhage risk.
Wang T; Fu W; Song S; Han Y; Yao L; Lu Y; Zheng J; Wang J
Exp Biol Med (Maywood); 2018 May; 243(9):749-753. PubMed ID: 29763368
[TBL] [Abstract][Full Text] [Related]
33. Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder.
Bobińska K; Szemraj J; Czarny P; Gałecki P
J Affect Disord; 2016 Nov; 205():119-129. PubMed ID: 27434116
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women.
Andrade VL; Petruceli E; Belo VA; Andrade-Fernandes CM; Caetano Russi CV; Bosco AA; Tanus-Santos JE; Sandrim VC
Clin Biochem; 2012 Apr; 45(6):412-5. PubMed ID: 22285381
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin therapy decreases MMP-9 levels in obese women.
Andrade VL; do Valle IB; Sandrim VC
J Clin Pharmacol; 2013 Oct; 53(10):1072-7. PubMed ID: 23913656
[TBL] [Abstract][Full Text] [Related]
36. Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma.
Hirata H; Okayama N; Naito K; Inoue R; Yoshihiro S; Matsuyama H; Suehiro Y; Hamanaka Y; Hinoda Y
Carcinogenesis; 2004 Dec; 25(12):2379-84. PubMed ID: 15319295
[TBL] [Abstract][Full Text] [Related]
37. Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study.
Wu P; Hua Y; Tan S; Li M; Shu Y; Fang G
Int J Clin Exp Pathol; 2015; 8(4):4165-70. PubMed ID: 26097608
[TBL] [Abstract][Full Text] [Related]
38. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis.
Söder PO; Meurman JH; Jogestrand T; Nowak J; Söder B
J Periodontal Res; 2009 Aug; 44(4):452-8. PubMed ID: 18973519
[TBL] [Abstract][Full Text] [Related]
40. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort.
Srivastava P; Kapoor R; Mittal RD
Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
